Mal-(CH2)5-Val-Cit-PAB-Eribulin

Mal-(CH2)5-Val-Cit-PAB-Eribulin 是抗体偶联药物的一部分 (drug-linker conjugate for ADC)，具有抗癌活性，它由抗微管剂Eribulin 和linker Mal-(CH2)5-Val-Cit-PAB 组成。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
500ug

￥13350.00

10680.00

- +
1mg

￥16875.00

13500.00

- +
5mg

￥41137.00

32910.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx34936
CAS: 2130869-21-3
别名:
分子式: C69H97N7O19
分子量: 1328.54
纯度: >98%
溶解度:
储存: 4°C, protect from light, stored under nitrogen
库存: 现货

Background

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB[1].

Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules[2].

[1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. Patent US20170252458A1.
[2]. Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174.